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Abstract
Background: Celiac disease is a complex chronic immune-mediated disorder of the small intestine. Today, the
pathobiology of the disease is unclear, perplexing differential diagnosis, patient stratification, and decision-making
in the clinic.
Methods: Herein, we adopted a next-generation sequencing approach in a celiac disease trio of Greek descent to
identify all genomic variants with the potential of celiac disease predisposition.
Results: Analysis revealed six genomic variants of prime interest: SLC9A4 c.1919G>A, KIAA1109 c.2933T>C and c.
4268_4269delCCinsTA, HoxB6 c.668C>A, HoxD12 c.418G>A, and NCK2 c.745_746delAAinsG, from which NCK2 c.
745_746delAAinsG is novel. Data validation in pediatric celiac disease patients of Greek (n = 109) and Serbian
(n = 73) descent and their healthy counterparts (n = 111 and n = 32, respectively) indicated that HoxD12 c.
418G>A is more prevalent in celiac disease patients in the Serbian population (P < 0.01), while NCK2 c.745_
746delAAinsG is less prevalent in celiac disease patients rather than healthy individuals of Greek descent (P = 0.
03). SLC9A4 c.1919G>A and KIAA1109 c.2933T>C and c.4268_4269delCCinsTA were more abundant in patients;
nevertheless, they failed to show statistical significance.
Conclusions: The next-generation sequencing-based family genomics approach described herein may serve as
a paradigm towards the identification of novel functional variants with the aim of understanding complex
disease pathobiology.
Keywords: Celiac disease, Genomic variants, Family genomics, Next-generation sequencing, Disease
predisposition
Background
Celiac disease is a complex chronic immune-mediated dis-
order of the small intestine. Today, the pathobiology of the
disease is unclear, perplexing differential diagnosis, patient
stratification, and decision-making in the clinic. Genetics
has been reported to play a key role. The HLA-DQ2 gene is
identified in up to 95 % of celiac disease patients, while
most of the remaining patients have the HLA-DQ8 gene.
Notwithstanding, the Chinese and Japanese populations
(devoid of HLA-DQ2) are not expected to develop the
disease, yet this is not true for the individuals with the
HLA-DQ8 gene. Celiac disease is also associated with an
extended ancestral haplotype that is defined by class I and
II HLAs (A, B, DR, DQ). Notably, HLA-DQ2 and/or HLA-
DQ8 expression is necessary but not sufficient for disease
development. Thus, other genes are anticipated to be in-
volved. Indeed, genome-wide association studies (GWAS)
have revealed 26 non-HLA genetic loci-associated celiac
disease and other autoimmune or chronic immune
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disorders (diabetes mellitus type I, rheumatoid arthritis) [1,
2]. In 2008 to 2011, several new celiac disease risk loci have
been identified [3–5], bringing the number of known loci
(including the HLA one) to 40 and indicating genes and
gene regulatory elements of paramount importance. In
2015, five new genetic loci were identified, being independ-
ent of HLA-DQA1 and HLA-DQB1 and associated with ce-
liac disease predisposition [6].
Although a genetic component has been described,
disease occurrence has been also associated with en-
vironmental factors and gut microbiome. In all cases,
gluten has been identified as the environmental trigger
of the disease, leading to the stimulation of gluten-
specific T cells. Differential diagnosis is still a major
issue. Although a gold standard diagnostic approach
has been defined (endoscopy with biopsy of the small
intestine coupled to positive disease serology), several
pathological conditions have been reported sharing
similar mucosal transformations with celiac disease as
well as other autoimmune disorders (thyroid disease,
Addison disease, autoimmune liver disease, Sjögren
syndrome) that occur ten times more frequently in
celiac disease patients often masking celiac disease
symptoms. Disease management options are restricted
to a gluten-free lifestyle, which ultimately fails to
protect patients from disease symptoms due to its
chronic nature. Can we delineate individual variability
towards differential diagnosis? Can we highlight the
disease mechanisms in question to assist disease
management?
So far, findings account for 49 % of the genetic basis of
the disease. As in other immune-mediated diseases, gen-
etic predisposition to celiac disease remains unresolved as
we still need to explain the remaining major fraction of
heritability, including rare as well as additional common
risk variants. Causal variants and genes still need to be
identified and/or more finely localized. In this context, the
Immunochip Consortium was developed to explore com-
prehensive datasets containing common, low-frequency,
and rare variants in related diseases (autoimmune thyroid
disease, ankylosing spondylitis, Crohn disease, celiac dis-
ease, IgA deficiency, multiple sclerosis, primary biliary cir-
rhosis, psoriasis, rheumatoid arthritis, systemic lupus
erythematosus, type 1 diabetes mellitus, and ulcerative
colitis) [7].
As expected, the advent of technology and, in particu-
lar, next-generation sequencing has provided unprece-
dented opportunities to delineate disease pathobiology
as well as inter-individual differences [8, 9]. Herein, we
propose a multi-step next-generation sequencing-based
family genomics approach, piloted in a celiac disease trio
of Greek descent to identify novel genomic variants of
functional significance with the aim of understanding
disease pathobiology.
Methods
Case selection, DNA isolation, and whole-genome
sequencing
A seven-member Greek family has been recruited (in-
formed consents have been obtained), and a trio analysis
(III-1, III-2, IV-3) has been performed using the celiac dis-
ease model (Additional file 1: Figure S1). A family-based
design was employed rather than a population-based de-
sign, as the former is generally considered to be robust
against population admixture and stratification and may
yield both within- and between-family information [10].
Genomic DNA isolation was performed from saliva using
the Oragene collection kit (DNA Genotek, Ontario,
Canada) (Serbian cohort) and peripheral blood using an
automated system (MagNA Pure Compact, Roche, Basel,
Switzerland) (Greek cohort). Whole-genome sequencing
was performed using Complete Genomics’ (CA, USA)
DNA nanoarray platform [11]. DNA sequencing coverage
was 110×. Only high-quality call variants were included in
the analysis (>93 %). Genomes were aligned with the hg19
reference genome.
Bioinformatics and in silico analyses
Next-generation sequencing data (Complete Genomics
Inc., CA) were analyzed using Ingenuity Variant Analysis
version 3.1.2 (Ingenuity® Systems, www.ingenuity.com).
This is a well-established software that identifies associa-
tions between phenotypes, defined by the user by classi-
fication of the tested individuals, and variants in the
sequenced genome. Upon classification of the family
members by phenotype (celiac vs. normal), a number of
variants were listed; the output was filtered into a
smaller variant list upon classification of the family
members by those being celiac patients vs. those who
were healthy and known not to be celiac disease sub-
jects. The genetic model used for this comparison was of
an autosomal dominant model, since it traces the genetic
inheritance from mother (III-2) to daughter (IV-3) in a
highly penetrant form. A total of 263 genes followed an
autosomal dominant pattern, and 227 variants were
identified in the genetic model. Out of these, 6 genes
and 7 variants were identified in the biological/pheno-
type pattern of celiac disease, due to either the past asso-
ciation of the genes considered or via the biological
significance as determined by the IVA software.
Due to the large amount of variants which are nor-
mally present in the genome, even when excluding in-
tronic sequences, several filtering steps are used in data
analysis to include only the genes which are likely to be
causative in the final output connected with just the dis-
ease of interest, in this case—celiac disease. All variants
were filtered according to the analysis required, using
custom scripts and Complete Genomics Analysis Tools
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(CGA™ Tools). The filtering cascade utilized in the
present data analysis is as follows:
1. Confidence: Only variants with call quality at least
20.0 in cases or at least 20.0 in controls (i.e., 99 %
call accuracy) were included.
2. Common variants: All variants observed to have an
allele frequency ≥3.0 % of the genomes in the 1000
genomes project OR ≥3.0 % of the public Complete
Genomics genomes OR ≥3.0 % of the NHLBI ESP
exomes were excluded.
3. Predicted deleterious: Only variants that are
experimentally observed to be associated with a
phenotype (Pathogenic, Possibly Pathogenic,
Unknown Significance OR established gain of
function in the literature OR gene fusions OR
inferred activating mutations by Ingenuity OR
predicted gain of function by BSIFT OR in a
microRNA binding site OR Frameshift, in-frame
indel, or stop codon change OR Missense and not
predicted to be innocuous by SIFT OR disrupt splice
site up to 2.0 bases into intron OR deleterious to a
microRNA OR structural variant) were kept.
4. Genetic analysis: Only variants with the following
genotype characteristics were kept: associated with
gain of function OR heterozygous_alt OR
haploinsufficient OR heterozygous OR homozygous
OR heterozygous_amb OR compound_heterozygous
OR hemizygous AND occur in at least 2 of the case
samples at the gene level in the Case samples AND
not which are associated with gain of function OR
heterozygous_alt OR haploinsufficient OR
heterozygous OR homozygous OR
heterozygous_amb OR compound_heterozygous OR
hemizygous AND occur in at least 1 of the control
samples at the variant level in the control samples.
5. Biological context: Only variants that are within 1
hop (direct targets) of upstream regulators or
downstream regulatory targets of such genes and
that are known or predicted to affect celiac disease.
Variants of interest were annotated with Annovar in
Galaxy [12] and compared with NCBI dbSNP build
137 (http://www.ncbi.nlm.nih.gov/projects/SNP/snp_su
mmary.cgi), 69 reference genomes from Complete Ge-
nomes (http://www.completegenomics.com/publicdata/
69Genomes/), and GWAS (http://www.genome.gov/
gwastudies) to determine their novelty or otherwise.
To obtain a list of variants of potential functional sig-
nificance, we employed protein variation effect
analyzer (PROVEAN) v1.1.3 (PROVEAN human gen-
ome variants tool) that provides both scale-invariant
feature transform (SIFT) [13] and PROVEAN [14]
predictions for a given list of human genome variants
as well as accessory information (dbSNP rs IDs, gene de-
scription, PFAM domain, GO terms, etc.). PROVEAN is
able to make predictions for any type of protein sequence
alteration, including single or multiple amino acid substitu-
tions, deletions, and insertions [15]. Additionally, Variant
Effect Predictor [16] and RegulomeDB [8] were employed
to allow further data interrogation.
Downstream molecular analysis
Selected variants were subsequently validated in pediatric
celiac disease patients of Greek (n = 109) [17] and Serbian
(n = 73) [18] descent and their healthy counterparts (n =
111 and n = 32, respectively). The diagnosis of celiac disease
was based on the criteria of the European Society for Paedi-
atric Gastroenterology, Hepatology and Nutrition (ESP-
GHAN) [19]. For children diagnosed prior to 1990, the
“Interlaken criteria” were applied. The Ethics Committee of
University Children’s Hospital, University of Belgrade, and
the Review Board of “Aghia Sophia” Children’s Hospital
have approved the study.
Amplification was carried out according to the
KAPA2G Fast HotStart protocol (KAPABIOSYSTEMS,
MA, USA); detailed information per SNP amplification
conditions is available upon request. For SLC9A4
c.1919G>A, an allele-specific polymerase chain reaction
(PCR) assay was developed (two alternative reverse
primers hybridizing exclusively either to the wild-type
or the mutant allele). For NCK2 c.745_746delAAinsG,
PCR products were subjected to XcmI (New England
Biolabs, MA, USA) restriction endonuclease analysis at
37 °C for 1.15 h and subsequent enzyme deactivation
(65 °C, 20 min). Restriction fragments were visualized
by 3 % agarose gel electrophoresis following ethidium
bromide or Midori Green staining. For HoxD12
c.418G>A, HoxB6 c.668C>A, and KIAA1109 c.2933T>C
and c.4268_4269delCCinsTA, a PCR-based conven-
tional Sanger resequencing approach was employed.
Capillary electrophoresis was performed on the ABI
Prism 3130xl DNA Analyzer (Applied Biosystems).
Sanger sequencing was also employed to ensure PCR-
RFLP and allele-specific PCR method verification.
Statistical analysis
Herein, a thorough statistical review and analysis has been
attempted, having always in mind that we used the celiac
disease model (trio analysis) as a reason to conduct a
more refined approach in searching/genotyping the re-
sulted variants in a selective population of celiac disease of
Greek and Serbian descent. We tested for deviations from
HWE using the chi-square goodness of fit test and princi-
pal component analysis. Considering that the χ2 approxi-
mation can be poor when there are low genotype counts,
a Fisher exact test (R genetics package) was also used, as it
does not rely on the χ2 approximation [20]. Tests were
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Fig. 1 Distribution of newly identified risk variants in Greek and Serbian populations. a HoxD12 c.418G>A is more abundant in pediatric celiac
disease patients of Greek and Serbian descent, reaching statistical significance (**P < 0.01) in the Serbian population. b NCK2 c.745_746delAAinsG
is more abundant in healthy individuals of Greek and Serbian descent, reaching statistical significance (*P = 0.03) in the Greek population
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performed as two-tailed, and differences were considered
statistically significant when P < 0.05. Focusing on case-
control phenotypes, we tested the null hypothesis of no
association between rows and columns of the 2 × 3 matrix
that contains the counts of the three genotypes (the two
homozygotes and the heterozygote) among cases and con-
trols. Again, a Fisher exact test was preferred (to evaluate
genotype and allele frequencies), as it is computationally
more demanding, but it is easily implemented in R. We
also performed the Armitage test (Monte Carlo method; it
obtains results that are closer to an exact test, since the
classical Cochran-Armitage trend test is based on approxi-
mation) [20].
Results and discussion
Whole-genome sequencing analysis of trio reveals newly
identified genetic risk variants for pediatric celiac disease
Our multi-step next-generation sequencing-based family
genomics approach revealed six genomic variants of
prime interest: SLC9A4 c.1919G>A, HoxD12 c.418G>A,
KIAA1109 c.2933T>C and c.4268_4269delCCinsTA, HoxB6
c.668C>A, and NCK2 c.745_746delAAinsG. Susceptibility
to celiac disease (CELIAC6) and to autoimmunity (AIS5)
has been previously mapped to the 4q27 region, within a
linkage disequilibrium block encompassing KIAA1109,
TENR, IL2, and IL21 genes [21]. So far, the most significant
linkage outside the HLA region refers to rs13119723 (P =
2.0 × 10−7 in the KIAA1109 gene on chromosome 4q27).
Zhernakova and coworkers [2] hypothesized that the
KIAA1109/TENR/IL2/IL21 susceptibility region reported by
van Heel and coworkers [21] might represent a general risk
locus for multiple autoimmune diseases. Even though sev-
eral CELIAC6 genomic variants have been reported [1, 2, 4,
21], this is the first time such a disease association is
revealed for KIAA1109 c.2933T>C and c.4268_4269delC-
CinsTA. SLC9A4 c.1919G>A, HoxD12 c.418G>A, HoxB6
c.668C>A, and NCK2 c.745_746delAAinsG are also re-
ported for the first time as celiac disease risk variants
(Fig. 1).
NCK2 c.745_746delAAinsG has not been annotated in
either dbSNP or the 1000 Genomes Project/exome vari-
ant server data, and hence, it may be considered to be
novel. NCK2 codes for Human Nck2 (hNck2), a 380-
residue adapter protein consisting of three SH3 domains
and one SH2 domain. Nck2 plays a pivotal role in con-
necting and integrating signaling networks constituted
by transmembrane receptors, such as ephrinB and effec-
tors critical for cytoskeletal dynamics and remodeling
[22–25]. A transient Nck2/PINCH-1 association process
has been also reported that may trigger rapid focal adhe-
sion turnover during integrin signaling, mediating cell
shape change and migration [26, 27]. We showed that
the novel variant identified herein results in a single
amino acid change (p.K249E), being this exact amino
acid that is reported of fundamental importance during
the abovementioned Nck2 SH3 domain protein-protein
interactions (Fig. 2a) [22, 26, 27]. p.K249E could severely
alter this network of polar interactions and affect the
interaction between the two proteins (Fig. 2b). In 2014,
Nadalutti et al. [28] observed that celiac patient IgA
antibodies disturb the extracellular protein cross-linking
function of transglutaminase 2, thus altering cell-
extracellular matrix interactions and thereby affecting
endothelial cell adhesion, polarization, and motility.
In silico analyses
To ascertain whether the variants of interest have func-
tional significance, in silico analysis was performed using
Fig. 2 a View of the SH3-3/LIM4 binding interface as previously shown by NMR spectroscopy [26]. The Nck2 DH3 domain interface is shown in
gray and the PINCH-1 LIM4 domain in green. K249 interacts with E233 and is part of a network connecting R192 of LIM4 and N250 of SH3. b
Structural model of the mutant p.K249E and the potential effect in the interactions between SH3 and LIM4
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PROVEAN prediction SIFT prediction Variant effect predictor
Variation type Score Prediction Score Prediction Consequence Impact PolyPhen LoFtool
SLC9A4 c.1919G>A 640 R K Single AA change −0.67 Neutral 0.140 Tolerated Frameshift variant High – 0.911
NCK2 c.745_746delAAinsG 249 K E Single AA change −1.97 Neutral 0.010 Damaging Frameshift variant High – 0.223
HOXD12 c.418G>A 140 A T Single AA change −0.01 Neutral 0.201 Tolerated Frameshift variant High – 0.432
KIAA1109 c.2933T>C 978 I T Single AA change −0.25 Neutral 0.187 Tolerated Frameshift variant High – 0.845
c.4268_4269delCCinsTA 1423 T I Single AA change −1.22 Neutral 0.108 Tolerated Missense variant Moderate Benign (0.031) 0.845
HOXB6 c.668C>A 223 A D Single AA change −.029 Neutral 0.230 Tolerated Frameshift variant High – –
Source: PROVEAN v1.1.3 (PROVEAN human genome variants tool, http://provean.jcvi.org/genome_submit_2.php?species=human) and Variant Effect Predictor (http://grch37.ensembl.org/Homo_sapiens/Tools/VEP).
Assembly: GRCh37. PROVEAN introduces a delta alignment score based on the reference and variant versions of a protein query sequence with respect to sequence homologs (NCBI NR protein database through
BLAST, http://www.ncbi.nlm.nih.gov/). The default score threshold was set at −2.5 for binary classification (deleterious <−2.5 vs. neutral > −2.5). Similarly, (through PSI-BLAST, http://blast.ncbi.nlm.nih.gov/Blas-
t.cgi?CMD=Web&PAGE=Proteins&PROGRAM=blastp&RUN_PSIBLAST=on), SIFT (http://sift.jcvi.org/) may be applied to naturally occurring non-synonymous variants. SIFT score ranges from 0 to 1. A SIFT score of ≤0.05
corresponds to a “damaging” prediction, whereas a SIFT score >0.05 predicts that the variant is likely to be “tolerated.” VEP; Consequence—consequence type of this variation, Impact—a subjective classification of the
severity of the variant consequence (high: the variant is assumed to have disruptive impact in the protein, probably causing protein truncation or loss of function or triggering nonsense mediated decay, moderate: a
non-disruptive variant that might change protein effectiveness, low: assumed to be mostly harmless or unlikely to change protein behavior, modifier: usually non-coding variants affecting non-coding genes, where pre-
dictions are difficult or there is no evidence of impact), PolyPhen—the PolyPhen prediction and/or score, LoFtool—provides a per-gene rank of genic intolerance and consequent susceptibility to disease based on the














the SIFT and PROVEAN algorithms [13, 14], as well as
Variant Effect Predictor [16] and Regulome DB [8]. As
summarized in Table 1, analyses yielded that all variants
share an effect to protein structure, which in the case of
NCK2 c.745_746delAAinsG is considered to be dam-
aging. Regulome DB questioned a possible role of the
variants of interest in terms of transcription factor bind-
ing sites, chromatin states, eQTLs, differentially methyl-
ated regions, validated functional SNPs and DNase
sensitivity. All variants had minimum or no impact
(Additional file 2: Table S1).
Replication analyses
Replication analyses were carried out in two cohorts to
account for population differences. We found that
NCK2 c.745_746delAAinsG is a novel variant that is
more abundant in healthy individuals, reaching statistical
significance (P = 0.03) in the Greek population. More-
over, HoxD12 c.418G>A, a frameshift variant, was more
abundant in pediatric celiac disease patients, reaching
statistical significance (P < 0.01) in the Serbian popula-
tion. When celiac disease risk assessment is considered,
it is important to note that apart from genotype data, re-
cords related to family history along with gender and
country of residence should not be disregarded [29]. In
both Greek and Serbian patients, SLC9A4 c.1919G>A
and KIAA1109 c.2933T>C and c.4268_4269delCCinsTA
were more abundant in patients; nevertheless, they failed
to show statistical significance, possibly due to small
sample sizes. All the studied variants satisfied the
Hardy-Weinberg equilibrium. All variants were verified
as non-frequent ones in agreement with PROVEAN’s
scoring scheme, separating disease-associated variants
from common ones [14]. Genotype frequencies (%) are
summarized in Fig. 1 and Table 2.
Conclusions
In relation to disease diagnosis and prognosis, data inter-
pretation requires an understanding of the variation in
risk-associated variants. In celiac disease, in particular,
this knowledge is still largely lacking. As whole-genome
and/or whole-exome sequencing approaches begin to be
employed in clinical care, the understanding of detected
sequence variations on diagnosis (and prognosis) is still
not a trivial undertaking. We envisage that the clinical
implementation of next-generation sequencing will play
a crucial role in delineating inter-individual variability
and identification of novel variants towards improved
therapeutic modalities. Herein, we propose a multi-step
next-generation sequencing-based family genomics ap-
proach, similar to our previous conducted cancer gen-
omics study [30], but piloted towards a complex genetic
disease, such as celiac disease, to analyze a family trio of
Greek descent to identify novel genomic variants of
functional significance with the aim of understanding
complex disease pathobiology. Recently, we have out-
lined the paradigm of pharmacometabolomics-aided
pharmacogenomics in autoimmune diseases to address
the interplay of genomic and environmental influences
with information technologies to facilitate data analysis
as well as sense- and decision-making on the basis of
synergy between artificial and human intelligence. We
propose that better-informed, rapid, and cost-effective
“omics” studies need the implementation of holistic and
multidisciplinary approaches [31].
Additional files
Additional file 1: A seven-member Greek family has been recruited
(informed consents have been obtained), and a trio analysis (III-1, III-
2, IV-3) has been performed using the celiac disease model. (PNG
136 kb)
Additional file 2: Regulome DB questioned a possible role of the
variants of interest in terms of transcription factor binding sites,
chromatin states, eQTLs, differentially methylated regions, validated
functional SNPs and DNase sensitivity. All variants had minimum or no
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Table 2 Genotyping data of celiac disease pediatric patients of Greek and Serbian descent and healthy individuals
Population groups Genotype frequency (%)
HoxB6 c.668C>A SLC9A4 c.1919G>A KIAA1109 c.2933T>C KIAA1109 c.4268_4269delCCinsTA
TT GG GT AA GG AG TT CC CT CC/CC TA/TA CC/TA
Healthy individuals of Greek descent 0 100 0 0 96 4 86 1 13 100 0 0
Patients of Greek descent 0 100 0 0 93 7 81 2 16 98 0 2
Healthy individuals of Serbian descent 0 100 0 0 97 3 80 0 20 100 0 0
Patients of Serbian descent 0 100 0 0 93 7 81 0 19 100 0 0
In both Greek and Serbian patients, SLC9A4 c.1919G>A and KIAA1109 c.2933T>C and c.4268_4269delCCinsTA were more abundant in patients; nevertheless, they
failed to show statistical significance, possibly due to a small sample size
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